AB Science SA

AB Science announces a voluntary hold in the clinical studies of masitinib worldwide

01 Jun 2021 00:59:55 By Nasdaq GlobeNewswire

AB Science communicates results from Phase 3 study evaluating masitinib in prostate cancer

26 May 2021 13:18:48 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Tuesday May 25, 2021 on masitinib results in Prostate Cancer

21 May 2021 12:01:41 By Nasdaq GlobeNewswire

AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting

20 May 2021 12:06:59 By Nasdaq GlobeNewswire

AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities

30 Apr 2021 12:45:24 By Nasdaq GlobeNewswire

AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint

29 Apr 2021 13:05:11 By Nasdaq GlobeNewswire

AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government

14 Apr 2021 12:02:19 By Nasdaq GlobeNewswire

AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19

06 Apr 2021 01:49:05 By Nasdaq GlobeNewswire

AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer

31 Mar 2021 11:58:45 By Nasdaq GlobeNewswire

AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer's Disease

08 Mar 2021 02:02:16 By Nasdaq GlobeNewswire

AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer

23 Feb 2021 02:02:09 By Nasdaq GlobeNewswire

AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19

25 Jan 2021 02:26:50 By Nasdaq GlobeNewswire